EUVIMEDEUVIMED entdecken
ÄquivalenzstudieMultizentrische StudieRandomisierte kontrollierte Studie

Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results

Maurizio Martelli iD, Luca Ceriani iD, Giovannino Ciccone iD, Umberto Ricardi iD, Iryna Kriachok, Barbara Botto, Monica Balzarotti iD, Alessandra Tucci iD, Sara Veronica Usai, Vittorio Ruggero Zilioli iD, Elsa Pennese, Luca Arcaini iD und 37 weitere

Journal of Clinical Oncology · 2024-12 · 42 (34) · 4071-4083

DOI: 10.1200/jco-24-01373 ↗

Kurz gefasst

Äquivalenzstudie in der Zeitschrift Journal of Clinical Oncology, 2024-12. Verfasst von Maurizio Martelli und 48 weiteren Autor:innen. Beteiligte Einrichtung: Sapienza University, Division of Hematology, Department of Translational and Precision Medicine, Rome, Italy. Hauptthemen laut MEDLINE: Lymphoma, B-Cell, Mediastinal Neoplasms. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The role of consolidation radiotherapy in patients with primary mediastinal B-cell lymphoma (PMBCL) is controversial. METHODS The IELSG37 trial, a randomized noninferiority study, aimed to assess whether irradiation can be omitted in patients with PMBCL with complete metabolic response (CMR) after induction immunochemotherapy. The primary end point was progression-free survival (PFS) at 30 months after random assignment. Patients with CMR were randomly assigned to observation or consolidation radiotherapy (30 Gy). With a noninferiority margin of 10% (assuming a 30-month PFS of 85% in both arms), a sample size of 540 patients was planned with 376 expected to be randomly assigned. RESULTS The observed events were considerably lower than expected; therefore, primary end point analysis was conducted when ≥95% of patients were followed for ≥30 months. Of the 545 patients enrolled, 268 were in CMR after induction and were randomly assigned to observation (n = 132) or radiotherapy (n = 136). The 30-month PFS was 96.2% in the observation arm and 98.5% in the radiotherapy arm, with a stratified hazard ratio of 1.47 (95% CI, 0.34 to 6.28) and absolute risk difference of 0.68% (95% CI, –0.97 to 7.46). The 5-year overall survival (OS) was 99% in both arms. Nonrandomized patients were managed according to local policies. Radiotherapy was the only treatment in 86% of those with Deauville score (DS) 4 and in 57% of those with DS 5. The 5-year PFS and OS of patients with DS 4 (95.8% and 97.5%, respectively) were not significantly different from those of randomly assigned patients. Patients with DS5 had significantly poorer 5-year PFS and OS (60.3% and 74.6%, respectively). CONCLUSION This study, the largest randomized trial of radiotherapy in PMBCL, demonstrated favorable outcomes in patients achieving CMR with no survival impairment for those omitting irradiation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, B-CellMediastinal NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedYoung AdultAntineoplastic Combined Chemotherapy ProtocolsProgression-Free Survival

Autor:innen und Institutionen

  • Sapienza University, Division of Hematology, Department of Translational and Precision Medicine, Rome, Italy.
  • Institute of Oncology Research (IOR), Bellinzona, Switzerland.
  • Ente Ospedaliero Cantonale, Imaging Institute of Southern Switzerland, Lugano, Switzerland.
  • Università della Svizzera Italiana, Faculty of Biomedical Sciences, Lugano, Switzerland.
  • AOU Città della Salute e della Scienza di Torino and CPO Piemonte, Clinical Epidemiology Unit, Turin, Italy.
  • University of Turin, Department of Oncology, Turin, Italy.

ORCID-Profile: Maurizio Martelli, Luca Ceriani, Giovannino Ciccone, Umberto Ricardi, Monica Balzarotti, Alessandra Tucci, Vittorio Ruggero Zilioli, Luca Arcaini, Andrés J M Ferreri, Francesco Merli, Weili Zhao, Luigi Rigacci, David Hodgson, Elisa Lucchini, Michele Spina, Andrea Janikova, Kate Cwynarski, George Mikhaeel, Mats Jerkeman, Yana Stepanishyna, Umberto Vitolo, Armando Santoro, Alessandro Re, Jacopo Olivieri, Sally F Barrington, Ur Metser, Annibale Versari, Stephane Chauvie, Jan Walewski, Marek Trneny, Mary Gospodarowicz, Peter W M Johnson, Andrew Davies, Emanuele Zucca

Zitieren

APA

Martelli, M., Ceriani, L., Ciccone, G., Ricardi, U., Kriachok, I., Botto, B., Balzarotti, M., Tucci, A., Usai, S. V., Zilioli, V. R., Pennese, E., Arcaini, L., Dabrowska-Iwanicka, A., Ferreri, A. J. M., Merli, F., Zhao, W., Rigacci, L., Cellini, C., Hodgson, D., …, & International Extranodal Lymphoma Study Group (IELSG) (2024). Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results. Journal of Clinical Oncology, 42(34), 4071-4083. https://doi.org/10.1200/jco-24-01373

Vancouver

Martelli M, Ceriani L, Ciccone G, Ricardi U, Kriachok I, Botto B, et al. Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results. Journal of Clinical Oncology. 2024;42(34):4071-4083. doi:10.1200/jco-24-01373

BibTeX
@article{Martelli2024,
  author = {Martelli, Maurizio and Ceriani, Luca and Ciccone, Giovannino and Ricardi, Umberto and Kriachok, Iryna and Botto, Barbara and Balzarotti, Monica and Tucci, Alessandra and Usai, Sara Veronica and Zilioli, Vittorio Ruggero and Pennese, Elsa and Arcaini, Luca and Dabrowska-Iwanicka, Anna and Ferreri, Andrés J M and Merli, Francesco and Zhao, Weili and Rigacci, Luigi and Cellini, Claudia and Hodgson, David and Ionescu, Codruta and Minoia, Carla and Lucchini, Elisa and Spina, Michele and Fosså, Alexander and Janikova, Andrea and Cwynarski, Kate and Mikhaeel, George and Jerkeman, Mats and Di Rocco, Alice and Stepanishyna, Yana and Vitolo, Umberto and Santoro, Armando and Re, Alessandro and Puccini, Benedetta and Olivieri, Jacopo and Petrucci, Luigi and Barrington, Sally F and Malkowski, Bogdan and Metser, Ur and Versari, Annibale and Chauvie, Stephane and Walewski, Jan and Trneny, Marek and Cavalli, Franco and Gospodarowicz, Mary and Johnson, Peter W M and Davies, Andrew and Zucca, Emanuele and International Extranodal Lymphoma Study Group (IELSG), International Extranodal Lymphoma Study Group (IELSG)},
  title = {Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {34},
  pages = {4071--4083},
  doi = {10.1200/jco-24-01373}
}
Kostenlos starten →